Harvard Bioscience (NASDAQ:HBIO) Stock Bumped Down to Hold by StoneX

StoneX cut shares of Harvard Bioscience (NASDAQ:HBIO) from a speculative buy rating to a hold rating in a research report released on Wednesday morning,FinViz reports.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings raised Harvard Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Zacks Research assumed coverage on Harvard Bioscience in a research note on Tuesday, November 3rd. They issued a “hold” rating for the company. Finally, Benchmark raised their target price on Harvard Bioscience from $6.00 to $7.50 and gave the company a “speculative buy” rating in a report on Wednesday, August 12th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $6.75.

Harvard Bioscience Trading Up 4.5%

Shares of HBIO opened at $9.68 on Wednesday. The company has a current ratio of 1.87, a quick ratio of 0.98 and a debt-to-equity ratio of 4.94. The firm has a market capitalization of $44.04 million, a P/E ratio of -3.74 and a beta of 1.47. The stock’s fifty day simple moving average is $8.29 and its 200 day simple moving average is $6.55. Harvard Bioscience has a twelve month low of $4.00 and a twelve month high of $10.20.

Harvard Bioscience (NASDAQ:HBIO) last posted its earnings results on Tuesday, November 10th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.27. Harvard Bioscience had a negative net margin of 13.20% and a negative return on equity of 38.35%. The business had revenue of $22.20 million for the quarter, compared to analyst estimates of $21.80 million. On average, equities research analysts forecast that Harvard Bioscience will post -2.44 earnings per share for the current year.

Hedge Funds Weigh In On Harvard Bioscience

A hedge fund recently bought a new position in Harvard Bioscience stock. Citadel Advisors LLC acquired a new position in Harvard Bioscience, Inc. (NASDAQ:HBIO) during the second quarter, according to the company in its most recent filing with the SEC. The fund acquired 13,251 shares of the medical instruments supplier’s stock, valued at approximately $81,000. Citadel Advisors LLC owned approximately 0.29% of Harvard Bioscience at the end of the most recent reporting period. 80.87% of the stock is owned by institutional investors and hedge funds.

Harvard Bioscience News Roundup

Here’s some of the latest news about HBIO:

• Positive Sentiment: Third-quarter revenue rose 8% year over year to $22.2 million, topping the $21.8 million analyst estimate. The company also reported an adjusted per-share loss that was narrower than consensus expected. Harvard Bioscience Q3 results
• Positive Sentiment: Management reaffirmed its full-year 2026 revenue-growth outlook of 3%–5%. Fourth-quarter revenue guidance of $23.7 million–$25.5 million also brackets the $24.5 million consensus estimate, easing concern about a change in the outlook. Q3 financial results
• Neutral Sentiment: Project Viking remains on track for completion by the end of Q1 2027, but the update provides no new financial impact or change to the timeline. Q3 revenue and business update

About Harvard Bioscience

Harvard Bioscience, Inc. (NASDAQ: HBIO) develops, manufactures and supplies specialized tools, equipment and consumables used in biomedical research, drug discovery and related life science applications. Its products support work in areas such as cell biology, electrophysiology, gene delivery, organ-on-chip research and preclinical studies. The company’s portfolio includes laboratory instruments, tissue and organ perfusion systems, electrophysiology equipment, cell and molecular biology products, and related consumables.